Immuneering Corporation (IMRX)
NASDAQ: IMRX
· Real-Time Price · USD
2.15
0.10 (4.88%)
At close: Jun 06, 2025, 3:59 PM
2.17
0.93%
After-hours: Jun 06, 2025, 05:20 PM EDT
4.88% (1D)
| Bid | 2.13 |
| Market Cap | 77.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.77M |
| EPS (ttm) | -1.97 |
| PE Ratio (ttm) | -1.09 |
| Forward PE | -1.16 |
| Analyst | Buy |
| Ask | 2.2 |
| Volume | 735,081 |
| Avg. Volume (20D) | 199,409 |
| Open | 2.02 |
| Previous Close | 2.05 |
| Day's Range | 2.01 - 2.38 |
| 52-Week Range | 1.00 - 3.83 |
| Beta | 0.00 |
About IMRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+9.09%
Immuneering shares are trading higher. Needham rei...
Unlock content with
Pro Subscription
5 months ago
+0%
Immuneering shares are trading higher after the company released interim data from its Phase 2a trials of IMM-1-104 and IMM-6-415 in advanced RAS and RAF-mutant tumors.
